Skip to main content Skip to search Skip to main navigation

EU: Parliament Votes to Revise MDR and IVDR

On 23 October, the European Parliament has adopted a resolution to revise the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) to address ongoing implementation challenges and support patient access to essential medical devices by 2025.

Key elements of the resolution include:

  • Reducing Certification Bottlenecks: Streamlining certification processes and improving timelines and costs to ensure ongoing availability of critical medical devices and diagnostics.
  • Support for Innovation: Establishing an accelerated regulatory pathway for breakthrough and innovative medical technologies, particularly for orphan, pediatric, and other devices addressing unmet medical needs.
  • Enhanced tranparency and consistency across notofied bodies: Standardising assessment timelines, reducing administrative burdens, and improving consistency across notified bodies to aid manufacturers and increase market access predictability.
  • Support for SMEs: Prioritizing policies that help small and medium-sized enterprises (SMEs) navigate the regulatory landscape with fewer administrative challenges.
  • Improved Governance: Proposing a single governance structure to oversee the regulatory system, aiming for efficiency, sustainability, and improved patient outcomes.

Source:

EU: European Parliament resolution of 23 October 2024 on the urgent need to revise the Medical Devices Regulation (2024/2849(RSP))

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
What are the Basic Principles of Organisational Structures?

What are the Basic Principles of Organisational Structures?

Here's the answer:
Read more
Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

The ICH Guideline Q14 “Analytical Procedure Development” was published in November 2023. This forward-looking and regulatory-savvy document builds upon the content of ICH Q2(R2) “Validation of Analytical Procedures” and incorporates elements from ICH Q8 “Pharmaceutical Development” and ICH Q9(R1) “Quality Risk Management.”
Read more
EU: GMP Annex 19 Updated

EU: GMP Annex 19 Updated

The European Commission has published a revised version of Annex 19 “Reference and Retention Samples”. The update mainly affects requirements for reference and retention samples of parallel imported, parallel distributed and parallel traded medicinal products.
Read more
Previous
Next